Drug Profile

HM 17321

Alternative Names: HM-17321 ; LA-UCN 2; UCN2 analogue - Hanmi Pharmaceutical; Urocortin-2 analogue - Hanmi Pharmaceutical

Latest Information Update: 28 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hanmi Pharmaceutical
Class Heart failure therapies; Hormones; Obesity therapies; Peptides
Mechanism of Action CRF receptor type 2 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Obesity
Preclinical Heart failure; Musculoskeletal disorders

Most Recent Events

24 Aug 2026 HM 17321 licensed to Genentech worldwide except South Korea
04 Aug 2026 Hanmi Pharmaceuticals plans a phase II trial for Obesity in 2027
08 Jun 2026 Preclinical trials in Musculoskeletal disorders in South Korea (SC) prior to June 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com